Johnson & Johnson to settle talc baby powder investigation, will reportedly pay $700 million

Johnson & Johnson to settle talc baby powder investigation, will reportedly pay 0 million


In this photo illustration, a container of Johnson and Johnson baby powder is displayed on April 05, 2023 in San Anselmo, California. 

Justin Sullivan | Getty Images

Johnson & Johnson has reached a tentative settlement to resolve an investigation by more than 40 states into claims that the company misled patients about the safety of its talc baby powder and other talc-based products, the company said in a statement to CNBC on Tuesday. 

Notably, the settlement does not resolve the tens of thousands of consumer lawsuits, some of which are slated to go to trial this year, alleging that those talc-based products caused cancer.

Those cases have for decades caused financial and public relations trouble for J&J, which contends that its now-discontinued talc products are safe for consumers.

J&J said in an October securities filing that 42 states and Washington, D.C., had launched a joint investigation into its marketing of talc-based products. The company will pay $700 million to settle the probe, its CFO Joseph Wolk told the Wall Street Journal Tuesday.

Last year, J&J only set aside about $400 million to resolve U.S. state consumer protection claims.

Erik Haas, J&J’s worldwide vice president of litigation, confirmed the settlement in a statement to CNBC. He did not provide the payment amount or further details on the deal.

“Consistent with the plan we outlined last year, the company continues to pursue several paths to achieve a comprehensive and final resolution of the talc litigation,” Haas told CNBC. “As was leaked last week, that progress includes an agreement in principle that the Company reached with a consortium of 43 State Attorneys Generals to resolve their talc claims.”

Bloomberg first reported about the settlement earlier this month, citing sources familiar with the matter. 

J&J, which reported fourth-quarter results on Tuesday, has twice tried to resolve the consumer talc cases by offloading those liabilities into a subsidiary, LTL Management, and having that unit file for Chapter 11 bankruptcy protection. 

A New Jersey bankruptcy judge in July rejected the second bankruptcy attempt, stating that LTL Management wasn’t in sufficient financial distress. A U.S. appeals court in April dismissed the first bankruptcy attempt for the same reason. 

As part of the latest failed bankruptcy attempt, J&J proposed to pay $8.9 billion to talc claimants.

J&J said late last year that it is considering a third bankruptcy attempt as it tries to push forward with that proposal.

J&J ended sales of its talc-based baby powder globally last year.



Source

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar
Health

Eli Lilly hikes 2025 outlook, tops quarterly estimates as Mounjaro, Zepbound sales soar

The Eli Lilly logo is shown on one of the company’s offices in San Diego, California, on Sept. 17, 2020. Mike Blake | Reuters Eli Lilly on Thursday hiked its 2025 guidance and posted second-quarter earnings that topped estimates on strong demand for its blockbuster weight loss and diabetes drugs. The company raised its fiscal 2025 […]

Read More
Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval
Health

Eli Lilly’s obesity pill led to around 12% weight loss in closely watched late-stage trial, paving way for approval

A sign with the company logo sits outside of the headquarters of Eli Lilly in Indianapolis, Indiana, on March 17, 2024. Scott Olson | Getty Images Eli Lilly on Thursday said the highest dose of its daily obesity pill helped patients lose almost 12% of their body weight, or roughly 27 pounds, at 72 weeks in […]

Read More
Eli Lilly earnings are coming Thursday. Here’s what top analysts expect
Health

Eli Lilly earnings are coming Thursday. Here’s what top analysts expect

Many on Wall Street expect that Novo Nordisk ‘s loss has been Eli Lilly ‘s gain, and this will be good news for the Zepbound maker’s second-quarter results. Novo Nordisk’s stock has cratered about 47% since the start of the year, as doubts emerged about the outlook for its GLP-1 drugs, Ozempic for diabetes and […]

Read More